drugset / Trial / NCT06731153
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open-label, randomized phase II clinical study which recruits unresectable recurrent or metastatic triple-negative breast cancer resistant to immunotherapy.
Timeline
- Start
- 2024-12
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | SHR0302 | Unknown | — | — |
| Background | Eribulin | Small molecule | — | — |